In advanced-phase CML, resistance to imatinib mesylate is associated with point mutations in the Bcr-Abl kinase domain. A new generation of potent Abl kinase inhibitors is undergoing clinical evaluation. It is important to generate specific resistance profiles for each of these compounds, which could translate into combinatorial and sequential treatment strategies. Having characterized nilotinib (AMN107) against a large panel of imatinibresistant Bcr-Abl mutants, we investigated which mutants might arise under nilotinib therapy using a cell based resistance screen. In contrast to imatinib mesylate, resistance to nilotinib was associated with a limited spectrum of Bcr-Abl kinase mutations. Among these were mutations affecting the P-loop and T315I. Rarely emerging resistant colonies at a concentration of 400 nM nilotinib exclusively expressed the T315I mutation. With the exception of T315I, all of the mutations that were identified were effectively suppressed when the nilotinib concentration was increased to 2000 nM, which falls within the peak -trough range in plasma levels (3.6 -1.7 µ M) measured in patients treated with 400 mg bid. Our findings suggest that nilotinib might be superior to imatinib in terms of the development of resistance. However, our study indicates that clinical resistance to nilotinib may be associated with the predominant emergence of T315I.
Introduction
The tyrosine kinase inhibitor imatinib mesylate (Gleevec; Novartis Pharma) fundamentally changed the standard of care for the treatment of chronic myeloid leukaemia (CML). In the International Randomized Interferon versus STI571 Study (IRIS) trial, imatinib achieved a complete cytogenetic response rate of 84% in newly diagnosed CML patients after a 42-months follow-up. 1 However, in advanced-phase CML and Philadelphia chromosomepositive acute lymphoblastic leukaemia (Ph+ ALL), responses to imatinib may be of a short
For personal use only. on June 29, 2017 . by guest www.bloodjournal.org From duration. [2] [3] [4] [5] [6] [7] Clinical resistance to imatinib has been attributed to amplification of the Bcr-Abl gene, 8, 9 clonal evolution, [9] [10] [11] [12] [13] and most importantly, Bcr-Abl gene mutations that obviate binding to the drug target. 8, [14] [15] [16] [17] [18] [19] Consequently, alternative Bcr-Abl kinase inhibitors, such as PD166326, nilotinib (AMN107) or dasatinib (BMS-354825) have been developed. Nilotinib and dasatinib already entered clinical trials and displayed promising activity in patients with imatinib-resistant chronic and advanced phase CML, [20] [21] [22] [23] and imatinib-resistant Ph+ ALL, respectively. 21 These compounds are more potent than imatinib in suppressing Bcr-Abl tyrosine kinase activity and cell growth of Bcr-Abl-transformed cells, and are capable of suppressing imatinib-resistant, mutant forms of Bcr-Abl. [24] [25] [26] [27] [28] [29] [30] This is in line with structural data, suggesting different binding properties for imatinib and alternative Abl kinase inhibitors such as PD173955 and nilotinib to the Bcr-Abl kinase domain. [30] [31] [32] Thus, specific resistance profiles for different therapeutically used Abl kinase inhibitors can be expected to emerge in treated patients, and it may be important to know these resistant profiles upfront in order to guide therapeutic decisions. To fully characterize nilotinib, we evaluated it against a panel of Ba/F3 cell lines expressing imatinib-resistant Bcr-Abl. In order to identify specific resistance mutations in Bcr-Abl which could emerge under therapy with this new agent, we then evaluated nilotinib in the cell-based screening method which we have previously established.
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Materials and methods
Inhibitors
Nilotinib (AMN107) was dissolved in dimethyl sulfoxide (DMSO) to give a 10 mM stock solution which was and stored at -20°C. Imatinib mesylate was dissolved in water and 10 mM stock solutions were stored at -20°C.
For personal use only. on June 29, 2017 . by guest www.bloodjournal.org From Cell culture and DNA constructs Ba/F3 cells were maintained, transfected and transformed as described previously. 33 Point mutations that were either identified in the nilotinib-screen or that are known to be associated with imatinib resistance in patients with CML or Ph+ ALL were introduced in Mig EGFP Bcr-Abl p185 34,35 using the QuickChange mutagenesis kit (Stratagene, Amsterdam, the Netherlands). Mutant p185 was then subcloned as described before. 33 Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). Bcr-Abl-specific nested reversetranscription-polymerase chain reaction of the Bcr-Abl kinase domain was performed as described before. 33 Resistance screen
Screening for inhibitor-resistant colonies was performed as described previously. 33 
Western blot
Ba/F3 cells were cultured for 2.5 h without and in the presence of inhibitor at the indicated concentrations. Cell lysis, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotting were done as described previously. 36 Abl antibodies were obtained from Pharmingen (8E9) (BD Biosciences, Heidelberg, Germany) and Calbiochem- Novabiochem (Ab3) (Schwalbach, Germany). Antibodies to phosphotyrosine were purchased from Upstate Biotechnology (4G10) (Biozol, Eching, Germany) and Transduction (PY20) (BD Biosciences). Bands were visualized using the enhanced chemoluminescence system (ECL) system (Amersham, Braunschweig, Germany).
Results
Activity of nilotinib against known imatinib-resistant Bcr-Abl mutants
The autophosphorylation activity of the Bcr-Abl fusion protein in cells was quantified with a capture ELISA using a c-Abl-specific capture antibody, together with an enzyme-labeled antiphosphotyrosine antibody and a luminescent substrate. The background tyrosine kinase activity of c-Abl was too low to be detected. The effects of imatinib and nilotinib on Ba/F3 cell lines expressing wild-type or imatinib-resistant Bcr-Abl are shown in Table 1 
Screening for nilotinib-resistant Ba/F3 clones
Employing a cell-based screening system, we generated a total of 234 Ba/F3 cell clones displaying nilotinib-resistance. The frequency of resistant cell clones emerging in the presence of nilotinib at 50 nM, which corresponds to 2.5 times the IC50 value, was 1.9 per
For personal use only. on June 29, 2017 . by guest www.bloodjournal.org From million cells (Fig. 1) , and decreased with increasing nilotinib concentrations to 0.05 per million at 400nM (20- Fig. 3A and  33 ). At 400 nM nilotinib, resistant clones exclusively contained T315I, whereas at 4 µM imatinib, there were still 12 exchanges at 11 different positions ( Figure 3B ).
Analysis of nilotinib resistance mutations identified in the screen
Mutations identified in the nilotinib-screen were recreated using site-directed mutagenesis and expressed in Ba/F3 cells. In cell growth assays, dose-response curves indicated that all these mutations mediate resistance to nilotinib (Fig. 4 , Table 2 ). P-loop mutations shifted IC90
values from 87 nM for wt Bcr-Abl to concentrations ranging from 383 nM (Q252H) to 2640 nM (Y253H). However, proliferation of clones expressing weak (Q252H, E255K), and also strong P-loop mutations (Y253H, E255V) was effectively inhibited when the nilotinib concentration was increased to 4000 nM (Fig. 4) . F311I caused a moderate resistance to nilotinib (IC50: 121 nM, IC90: 467 nM). In contrast, in line with previous reports, 30,37 T315I
caused a complete resistance to nilotinib at concentrations of 4000 nM and above (Fig. 4 , Table 2 ). The double mutant Q252H/S349L displayed a cooperative reduction of inhibitor sensitivity compared to both single mutations (Fig. 4 , Table 2 ). Both exchanges at F359 were completely inhibited by 500 to 1000 nM nilotinib (Fig. 4) . In accordance with growth inhibition assays, Bcr-Abl autophosphorylation was suppressed in Ba/F3 cells expressing wild-type Bcr-Abl (Fig. 5A ). All mutants except T315I displayed complete suppression of Bcr-Abl autophosphorylation at concentrations ranging from 250 nM (F311I, F359V) to 4000nM (Y253H).
Discussion
The availability of small molecule kinase inhibitors specifically acting on different oncogeneic tyrosine kinases undoubtedly inaugurated new therapeutic options in a variety of neoplastic disorders. The Abl kinase inhibitor imatinib induces impressive and durable responses in chronic myeloid leukaemia, with a low risk of relapse and only a small 42, 43 This phenomenon is not specific for imatinib, since a resistance mutation in the FLT3 kinase domain has been described in a patient who received PKC412 for acute myeloid leukaemia, 44 and a T790M mutation in the epidermal growth factor gene (EGFR), which is homologous to the T315I mutation in Bcr-Abl, has been reported in patients with lung cancer resistant to the EGFR inhibitor gefitinib (Iressa). 45, 46 For imatinib, cellular IC50 values in Bcr-Abl-transformed cell lines are reported to be in the range of 200 to 400 nM. 15, 30, 47, 48 In contrast, cellular IC50 values of alternative Abl kinase inhibitors are below 10 nM for the pyridopyrimidine PD166326, 25, 26 14 nM for the trisubstituted purine analog AP23464, 28 20-60 nM for the aminopyrimidine nilotinib (AMN107), 30 and below 2.5 nM for the disubstituted pyrimidine derivative dasatinib (BMS-354825). 29 In addition, these novel compounds are capable of suppressing imatinib-resistant mutant forms of Bcr-Abl, with the exception of T315I. [24] [25] [26] [27] [28] [29] [30] 37 Bcr-Abl mutant is expected to be insensitive to nilotinib therapy. However, this does not address potential new mutations which might emerge under treatment with nilotinib.
We have recently reported results of a cell-based strategy that allows generation of imatinibresistant Ba/F3 cell clones in a high frequency. 33, 49 The pattern of mutations identified in these clones corresponded to the pattern observed in patients displaying imatinib resistant CML. 33 Our findings with nilotinib reported here point to significant advantages over imatinib Figure 4 . IC90 values and fold increase in comparison to Bcr-Abl wild-typeexpressing Ba/F3 cells were calculated using the resulting growth curves. For
